Ekec01n

[Ekec01n @RJDM7]

$rckt FDA approved! https://t.co/5RB4BpjeDV

[Ekec01n @RJDM7]

$SPCB https://t.co/buJtp0zC6b

[JC @j16425646]

(1/3) The $SPCB story is much better than I anticipated, and I believed the stock was worth $100+. It seems the company's $55.9mn backlog, may be at least $73 million too low.

[Ekec01n @RJDM7]

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher - https://t.co/hSFJ58LXrm

[Ekec01n @RJDM7]

$RCKT 🚀🚀Check out @StocktwitsNews message on Stocktwits https://t.co/2GM82JRuL7

[Ekec01n @RJDM7]

@BiotechAutist https://t.co/5RB4BpjeDV

[L'il Oaty @Lil__Oaty]

https://t.co/GFzymgsp1R

[John Zidar aka/ Stock Wizard @JohnZidar]

$RCKT - Rocket Pharmaceuticals
🔹Announces FDA Acceptance of BLA Resubmission of KRESLADI™
🔹For the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
🔹Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026
🔹All primary and secondary endpoints were met, and KRESLADI™ was well tolerated
🔹Rocket is eligible for a Rare Pediatric Disease Priority Review Voucher, should KRESLADI™ be approved

👆 3.7% PreM/ $3.65

[Ekec01n @RJDM7]

$rckt 📈📈🚀🚀🚀

[Ekec01n @RJDM7]

@Jason $OPEN

[Thomas James Investing @Thomas_james_1]

SUPER Important update on $OPEN

It finally got the $2.91 breakout, this is a huge level I’ve mentioned a few times, it means retail investors are now in control.

Now we want to see it break $4 and then $5 and then squeeze to $10+ in a couple of days.

This is HUGE for the bulls.

Long term we want to see a turnaround for Opendoor and for the business to build into a successful machine.

The discord and I are long on $OPEN from $2.91.

If you don’t have the time to watch it right now, be sure to Bookmark 📖 This post and watch it later!

I’m posting 20 of the BEST setups in the market this weekend, be sure to FOLLOW with NOTIFICATIONS ON 🔔 to get alerted when I post a new trade idea.

[Eric Jackson @ericjackson]

I obviously hope we bring @rabois back in the $OPEN fold.

Beyond just a returning embrace of the OGs, it would be awesome to have some other high profile investors come along for the ride.

People like

@chamath
@elonmusk
@EricTrump
@pulte

There’s so much to be excited about if OPEN reconnects to its Founder DNA to see its revival through

[EmanTheTrader @miller_eman]

Here comessssss $OPEN 🚀

Bookmark for the before and after

[Ekec01n @RJDM7]

$RCKT ,📈📣📣

[Jonathan Faison @jfais20]

$RCKT (L)

Seeing several rare disease names responding well to FDA commissioner remarks to start the week $QURE $NTLA $PHVS $STOK

Sentiment improvement alone enough to double IMO

[Citius Pharma @CitiusPharma]

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-Cxdl) Added to National Comprehensive Cancer Network (@NCCN) Clinical Practice Guidelines in #Oncology. Read the press release here: https://t.co/vHMlRSQFwM $CTXR $CTOR #OncNews

[Citius Pharma @CitiusPharma]

Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma. Read the press release here: https://t.co/TBFZX1YtEZ $CTXR #CTCL #FDAApproval

[The Instigator @Am_Blujay]

Being racist is a full time job

[INOVIO Pharmaceuticals @InovioPharma]

Lead investigator Dr. Angela Huttner was at #ECCMID2023 presenting the positive Phase 1b results for INO-4201 as an Ebola booster for rVSV-ZEBOV (Ervebo®). Read more: https://t.co/nVXHe5PiCs